CELGENE CORP /DE/

Delisted

CIK 816284fmd_0JG6MXN4ECKWGESBVDE4MDQ99FManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2007 to Sep 30, 2019, 47 periods

Income Statement · Annual · Millions · USD
Line item	FY2009	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018
Total revenues	2,690	3,626	4,842	5,507	6,494	7,670	9,256	11,229	13,003	15,281
Cost of revenue	216	307	426	299	340	386	420	438	461	587
Gross profit	2,351	3,202	4,274	5,086	6,022	7,178	8,741	10,747	12,512	14,678
Research and development	795	121	1,600	1,724	2,226	2,431	3,697	4,470	5,915	5,673
Selling, general and administrative	754	951	1,226	1,374	1,685	2,028	2,305	2,658	2,941	3,250
Operating income	842	990	1,443	1,746	1,809	2,519	2,255	3,166	4,707	5,191
Interest expense	2	13	43	63	92	176	311	500	522	741
Interest and investment income	77	45	26	15	22	28	31	30	105	45
Other non-operating income (expense)	60	(9)	(6)	(17)	(74)	(44)	48	(324)	24	337
Income before taxes	976	1,013	1,420	1,681	1,665	2,327	2,024	2,373	4,314	4,832
Income tax expense	199	132	102	225	216	328	421	373	1,374	786
Net income from continuing operations	777	880	1,317	1,456	1,450	2,000	1,602	2,000	2,940	4,046
Net income	777	881	1,317	1,456	1,450	2,000	1,602	1,999	2,940	4,046
Net income to common shareholders	777	881	1,318	1,456	1,450	–	–	–	–	–